Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast 2025-2034

About 25% of adults in the United States have non-alcoholic fatty liver disease (NAFLD). Out of these NAFLD patients, nearly 20% (accounting for 5% of the adult population) are affected by non-alcoholic steatohepatitis (NASH). It is reported that most individuals with NAFLD have a simple fatty liver without significant liver damage.

Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast Report Coverage

The “Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of non-alcoholic fatty liver disease (NAFLD). It projects the future incidence and prevalence rates of non-alcoholic fatty liver disease (NAFLD) across various populations. The study covers age, gender, and type as major determinants of the non-alcoholic fatty liver disease (NAFLD)-affected population. The report highlights patterns in the prevalence of non-alcoholic fatty liver disease (NAFLD) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of non-alcoholic fatty liver disease (NAFLD) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Non-alcoholic Fatty Liver Disease (NAFLD): Disease Overview

Non-alcoholic fatty liver disease (NAFLD), now newly renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is a condition where excess fat builds up in the liver. The condition can range from simple fat accumulation to more severe forms that cause liver damage, inflammation, and scarring. The risk of developing NAFLD increases with obesity, type 2 diabetes, high cholesterol, high blood pressure, and metabolic syndrome. Common symptoms include fatigue, abdominal pain, jaundice, and unexplained weight loss.

Non-alcoholic Fatty Liver Disease (NAFLD): Treatment Overview

The treatment approach for non-alcoholic fatty liver disease is usually focused on lifestyle changes, including a well-balanced diet and regular exercise. The patients are advised to lose 5-10% of their body weight, which can help in significantly improving liver health by reducing fat buildup and inflammation in the liver. Statins are often prescribed to people with NAFLD who also have high cholesterol. Fibrates are taken to lower triglyceride levels in the blood, which can be elevated in NAFLD patients.

Epidemiology

The non-alcoholic fatty liver disease (NAFLD) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for non-alcoholic fatty liver disease (NAFLD) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for non-alcoholic fatty liver disease (NAFLD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• An estimated 38% of the global population is affected by non-alcoholic fatty liver disease. This condition is rapidly increasing in prevalence, owing to factors like obesity, poor diet, and lack of physical activity.
• NAFLD ranks as the most common chronic liver condition in the United States, affecting an estimated 25% of the adult population.
• The estimated prevalence of NAFLD in adults is projected to reach 33.5% by 2030, highlighting a serious public health threat.
• Around 18% of pregnant women are affected by NAFLD, and pregnancy can worsen the condition due to natural hormonal changes, primarily due to the increased estrogen levels and the natural insulin resistance that typically occurs during pregnancy.

Country-wise Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology

The non-alcoholic fatty liver disease (NAFLD) epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of non-alcoholic fatty liver disease (NAFLD) varies between countries, owing to differences in the prevalence of risk factors (such as obesity, diabetes, high-fat diets, and low physical activity levels), lifestyle habits, environmental and genetic factors, and healthcare access. An AIIMS study, which reviewed published reports on non-alcoholic fatty liver disease in India, found that more than one-third (38%) of Indians are affected by fatty liver or NAFLD.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of non-alcoholic fatty liver disease (NAFLD) based on several factors.
• Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of non-alcoholic fatty liver disease (NAFLD) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of non-alcoholic fatty liver disease (NAFLD) epidemiology in the 8 major markets?
• What will be the total number of patients with non-alcoholic fatty liver disease (NAFLD) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of non-alcoholic fatty liver disease (NAFLD) in the 8 major markets in the historical period?
• Which country will have the highest number of non-alcoholic fatty liver disease (NAFLD) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of non-alcoholic fatty liver disease (NAFLD) during the forecast period of 2025-2034?
• What are the currently available treatments for non-alcoholic fatty liver disease (NAFLD)?
• What are the disease risks, signs, symptoms, and unmet needs of non-alcoholic fatty liver disease (NAFLD)?

This product will be delivered within 3-5 business days.